Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

News & Events

Wal-yan researchers welcomed at scientific meeting in New Zealand

More than 14 researchers from the Wal-yan Respiratory Research Centre will be welcomed as presenters and facilitators at The Thoracic Society of Australia and New Zealand and The Australia and New Zealand Society of Respiratory Science (TSANZSRS) Annual Scientific Meeting (ASM) this weekend.

News & Events

Keelan has ‘survived and thrived’, thanks to research

Ten-year-old Keelan Mullins is known to his mum Clare Hindle as her ‘miracle baby’. Keelan was born in March 2013 at 26 weeks’ gestation and weighing just 1096 grams.

News & Events

Preterm respiratory researchers share what World Prematurity Day means to them

Preterm researchers Dr Shannon Simpson (left) and Professor Jane Pillow (right) with Tony Sparks WA chairperson Amber Bates.

News & Events

Research into chronic lung disease in Indigenous children and a novel RSV treatment boosted thanks to WACRF grants

Wal-yan Respiratory Research Centre researchers will use almost $1.2 million in WA Child Research Fund grants to determine why Indigenous children develop bronchiectasis at such high rates after contracting bronchiolitis, and to test a promising novel treatment for respiratory syncytial virus (RSV).

Research

Treatment with inhaled aerosolised ethanol reduces viral load and potentiates macrophage responses in an established influenza mouse model

Treatment options for viral lung infections are currently limited. We aimed to explore the safety and efficacy of inhaled ethanol in an influenza-infection mouse model.

Research

Vitamin A and bronchopulmonary dysplasia: the next steps

Preterm infants are often vitamin A deficient, and vitamin A has functions that could mitigate the processes that lead to bronchopulmonary dysplasia. Therefore, supplementation of preterm infants with vitamin A to reduce the risk of bronchopulmonary dysplasia makes inherent sense.

Research

A phase I clinical trial assessing the safety, tolerability, and pharmacokinetics of inhaled ethanol in humans as a potential treatment for respiratory tract infections

Current treatments for respiratory infections are severely limited. Ethanol's unique properties including antimicrobial, immunomodulatory, and surfactant-like activity make it a promising candidate treatment for respiratory infections if it can be delivered safely to the airway by inhalation. Here, we explore the safety, tolerability, and pharmacokinetics of inhaled ethanol in a phase I clinical trial.

Research

Unravelling the respiratory health path across the lifespan for survivors of preterm birth

Many survivors of preterm birth will have abnormal lung development, reduced peak lung function and, potentially, an increased rate of physiological lung function decline, each of which places them at increased risk of chronic obstructive pulmonary disease across the lifespan. 

Research

A rapid semi-quantitative screening method to assess chemicals present in heated e-liquids and e-cigarette aerosols

Electronic cigarettes (e-cigarettes) lack regulatory status as therapeutic products in all jurisdictions worldwide. They are potentially unsafe consumer products, with significant evidence they pose a risk to human health. Therefore, developing rapid, economical test methods to assess the chemical composition of e-liquids in heated and unheated forms and the aerosols produced by e-cigarettes is crucial.

Research

The SPEC score—A quantifiable CT scoring system for primary ciliary dyskinesia

Structural lung changes seen on computed tomography scans in persons with primary ciliary dyskinesia are currently described using cystic fibrosis derived scoring systems. Recent work has shown structural changes and frequencies that are unique to PCD, indicating the need for a unique PCD-derived scoring system.